Company intelligence / Profile preview
Elicio Therapeutics
Boston, Massachusetts, United Stateselicio.com ↗
- Ownership
- Public · ELTX
- Employees
- ~32
- Development stage
- Phase 2
01
Overview
Completed enrollment of Phase 2 AMPLIFY-7P randomized study for ELI-002; disease-free survival event-driven interim analysis expected in Q3 2025. Phase 1a data showed strong concordance between T cell response and anti-tumor activity with antigen spreading beyond KRAS to other personalized tumor neo-antigens.[7]
- Therapeutic areas
- Oncology
- Modalities
- Cancer vaccinesimmunomodulatorsadjuvants
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $44.8M
- Total revenue
- $0
- Enterprise value
- $35.5M
Beyond the preview
Go deeper on Elicio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elicio Therapeutics.